Skip to main content
. Author manuscript; available in PMC: 2022 Dec 1.
Published in final edited form as: Oncogene. 2022 May 7;41(24):3328–3340. doi: 10.1038/s41388-022-02340-8

Fig. 3. MS40 selectively degrades WDR5 and the CRBN neo-substrates (IKZF1 and IKZF3) in cells.

Fig. 3

A Multiplexed quantitative proteomics analysis of MV4;11 cells (n = 5 replicates) post-treatment with 0.5 μM of MS40 versus DMSO for 6 h, which revealed WDR5, IKZF1 and LIMD1 to be most significantly downregulated, with a cut-off of P value less than 0.01 (defined by Student’s t test) and Log2 (fold-change or FC) over 0.5. B Immunoblotting for the indicated protein in MV4;11 and RS4;11 cells treated with DMSO or 0.5 μM of MS40N1, MS40, OICR-9429, pomalidomide, or OICR-9429 plus pomalidomide (1:1 molar ratio at 0.5 μM) for 18 h. C, D MS40 induced WDR5 and IKZF1 degradation is dose- and time-dependent in a panel of indicated cell lines.